Sequence Bio

Sequence Bio is a biotechnology company based in St.

John's, Newfoundland and Labrador, Canada, founded in 2013. The company focuses on utilizing the unique genetic characteristics of the Newfoundland population to identify genetic signals of disease. By integrating multi-omics data and real-world patient records, Sequence Bio accelerates the discovery of drug targets for both common and rare diseases. The company is a key participant in the NL Genome Project, which aims to sequence the genomes of approximately 100,000 individuals from Newfoundland. This initiative helps create highly-curated discovery cohorts that enhance drug target discovery. Sequence Bio offers services such as discovery cohort creation, systems biology and data integration, target discovery, and genomic research to support pharmaceutical and biotechnology firms in their drug development efforts. With a strong backing from notable investors and a dedicated team, Sequence Bio is committed to improving the success rate of new drug development and transforming healthcare through advanced genomic data and innovative approaches.